PE20060095A1 - Agonistas beta 2 y procesos para su preparacion - Google Patents

Agonistas beta 2 y procesos para su preparacion

Info

Publication number
PE20060095A1
PE20060095A1 PE2004000483A PE2004000483A PE20060095A1 PE 20060095 A1 PE20060095 A1 PE 20060095A1 PE 2004000483 A PE2004000483 A PE 2004000483A PE 2004000483 A PE2004000483 A PE 2004000483A PE 20060095 A1 PE20060095 A1 PE 20060095A1
Authority
PE
Peru
Prior art keywords
phenyl
processes
preparation
agonists
beta
Prior art date
Application number
PE2004000483A
Other languages
English (en)
Inventor
Mark Edward Bunnage
Paul Alan Glossop
Charlotte Alice Louise Lane
Russell Andrew Lewthwaite
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20060095A1 publication Critical patent/PE20060095A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/14—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Indole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

REFERIDA A COMPUESTOS DE FORMULA I DONDE (CH2)n-C(=O)Q1 ESTA EN POSICION META O PARA, n ES 1-2; Q1 ES (a) O (b) CUYOS R1, R2, R3 Y R4 SON CADA UNO H Y -N(R8)-Q2-A; Q2 ES ENLACE SENCILLO, ALQUILENO C1-C4, R8 ES H, ALQUILO C1-C4; p ES 1-2; A ES PIRIDILO, (c), (d) CUYOS R1, R2, R3, R4 Y R5 SON H, ALQUILO, HALO, ENTRE OTROS. TAMBIEN REFERIDA A PROCESOS PARA SU PREPARACION SIENDO PREFERIDOS: N-(2,6-DIMETOXIBENCIL)-2-(3{(2R)-2-[(2R)-2-HIDROXI-2-(4-HIDROXI-3-HIDROXIMETIL-FENIL)-ETILAMINO]-PROPIL}-FENIL)-ACETAMIDA; ACIDO 4-{([2-(3-{(2R)-2-[(2R)-2-HIDROXI-2-(4-HIDROXI-3-HIDROXIMETIL-FENIL)-ETILAMINO]-PROPIL}-FENIL)-ACETIL]-AMINO)-METIL}-BENZOICO; ENTRE OTROS. DICHOS COMPUESTOS SON UTILES EN ENFERMEDADES INFLAMATORIAS, ALERGICAS Y RESPIRATORIAS
PE2004000483A 2003-05-15 2004-05-11 Agonistas beta 2 y procesos para su preparacion PE20060095A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03010944A EP1477167A1 (en) 2003-05-15 2003-05-15 [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists
GBGB0329874.2A GB0329874D0 (en) 2003-05-15 2003-12-23 Compounds useful for the treatment of diseases

Publications (1)

Publication Number Publication Date
PE20060095A1 true PE20060095A1 (es) 2006-02-18

Family

ID=33454327

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000483A PE20060095A1 (es) 2003-05-15 2004-05-11 Agonistas beta 2 y procesos para su preparacion

Country Status (29)

Country Link
EP (2) EP1477167A1 (es)
JP (1) JP3966897B2 (es)
KR (1) KR100749990B1 (es)
CN (1) CN1791407A (es)
AP (1) AP2005003443A0 (es)
AR (1) AR044335A1 (es)
AT (1) ATE413879T1 (es)
AU (1) AU2004237952A1 (es)
BR (1) BRPI0410391A (es)
CA (1) CA2525006A1 (es)
CL (1) CL2004000963A1 (es)
CO (1) CO5700776A2 (es)
DE (1) DE602004017710D1 (es)
DK (1) DK1624868T3 (es)
EA (1) EA200501615A1 (es)
EC (1) ECSP056164A (es)
ES (1) ES2314395T3 (es)
GB (1) GB0329874D0 (es)
IS (1) IS8080A (es)
MA (1) MA27840A1 (es)
MX (1) MXPA05012329A (es)
NL (1) NL1026203C2 (es)
NO (1) NO20055854L (es)
OA (1) OA13165A (es)
PA (1) PA8603001A1 (es)
PE (1) PE20060095A1 (es)
TW (1) TW200505865A (es)
UY (1) UY28317A1 (es)
WO (1) WO2004100950A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2553789C (en) 2004-01-22 2011-07-19 Pfizer Inc. Sulfonamide derivatives for the treatment of diseases
EA009735B1 (ru) 2004-01-22 2008-02-28 Пфайзер Инк. Сульфонамидные производные для лечения заболеваний
EA200601510A1 (ru) * 2004-03-17 2007-04-27 Пфайзер Инк. Производные фенилэтаноламина в качестве бета-2-агонистов
WO2005092860A1 (en) * 2004-03-23 2005-10-06 Pfizer Limited Compounds for the treatment of diseases
CA2560368A1 (en) * 2004-03-23 2005-10-06 Pfizer Inc. Compounds for the treatment of diseases
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
US7994211B2 (en) 2005-08-08 2011-08-09 Argenta Discovery Limited Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
CA2667962A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
PT2231642E (pt) 2008-01-11 2014-03-12 Novartis Ag Pirimidinas como inibidores de quinase
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
MX2011007036A (es) 2008-12-30 2011-07-20 Pulmagen Therapeutics Inflammation Ltd Compuestos de sulfonamida para el tratamiento de trastornos respiratorios.
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
US9102671B2 (en) 2011-02-25 2015-08-11 Novartis Ag Compounds and compositions as TRK inhibitors
GB201601301D0 (en) * 2016-01-25 2016-03-09 Takeda Pharmaceutical Novel compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8528633D0 (en) * 1985-11-21 1985-12-24 Beecham Group Plc Compounds
US5629200A (en) * 1993-11-18 1997-05-13 Daicel Chemical Industries, Ltd. Production of optically active 2-amino-1-phenylethanol derivatives by asymetrical assimilation
US5561142A (en) * 1994-04-26 1996-10-01 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
WO1996035671A1 (en) * 1995-05-10 1996-11-14 Pfizer Inc. β-ADRENERGIC AGONISTS
US6090942A (en) * 1998-10-15 2000-07-18 Pfizer Inc. Process and intermediates for a β3 -adrenergic receptor agonist

Also Published As

Publication number Publication date
CA2525006A1 (en) 2004-11-25
NO20055854L (no) 2006-02-10
EP1624868B1 (en) 2008-11-12
OA13165A (en) 2006-12-13
ECSP056164A (es) 2006-04-19
NL1026203A1 (nl) 2004-11-16
WO2004100950A1 (en) 2004-11-25
CN1791407A (zh) 2006-06-21
JP2007503458A (ja) 2007-02-22
EP1624868B9 (en) 2009-08-12
EA200501615A1 (ru) 2006-06-30
IS8080A (is) 2005-10-20
ATE413879T1 (de) 2008-11-15
UY28317A1 (es) 2004-12-31
ES2314395T3 (es) 2009-03-16
AR044335A1 (es) 2005-09-07
DE602004017710D1 (de) 2008-12-24
CL2004000963A1 (es) 2005-03-18
DK1624868T3 (da) 2009-02-23
JP3966897B2 (ja) 2007-08-29
BRPI0410391A (pt) 2006-07-18
MXPA05012329A (es) 2006-01-30
EP1477167A1 (en) 2004-11-17
KR20060017607A (ko) 2006-02-24
CO5700776A2 (es) 2006-11-30
AP2005003443A0 (en) 2005-12-31
KR100749990B1 (ko) 2007-08-16
NL1026203C2 (nl) 2005-07-26
GB0329874D0 (en) 2004-01-28
MA27840A1 (fr) 2006-04-03
PA8603001A1 (es) 2004-12-16
EP1624868A1 (en) 2006-02-15
TW200505865A (en) 2005-02-16
AU2004237952A1 (en) 2004-11-25

Similar Documents

Publication Publication Date Title
PE20060095A1 (es) Agonistas beta 2 y procesos para su preparacion
PE20051136A1 (es) Derivados de sulfonamida
PE20120345A1 (es) Derivados de 2-(1h-pirrolo[2,3-b]piridin-5-iloxi)-n-fenilsulfonilbenzamida como inhibidores de proteinas anti-apoptoticas
ES2310333T3 (es) Derivados del acido antranilico, metodos para su preparacion y uso como inhibidores de dhodh.
PE20120136A1 (es) Compuestos derivados de n-acilsulfonamidas como inhibidores de bcl-2
RU2010140668A (ru) Ингибиторы активности протеинтирозинкиназы
AR045317A1 (es) Forma cristalina de agonista dl receptor adrenergico b2
PE20020220A1 (es) Compuestos de nitrilo de dipeptido como inhibidores de catepsina k
DE19675028I2 (de) N-Phenyl-N-(4-piperidinyl)-amide verwendbar als Analgetika
PE20081059A1 (es) Derivados de pirimidinas como inhibidores de la actividad de la tirosina quinasa de bruton (btk)
PE85999A1 (es) Derivados de fenil y aminofenil-alquilsulfonamida y urea
US20140113012A1 (en) Compounds and methods for inducing chondrogenesis
HUP0204226A2 (en) Quinazoline derivatives, pharmaceutical compositions containing them, their use and process for the preparation of the compounds
PE20040649A1 (es) Procedimiento para la preparacion de benzoilureas heterociclicamente sustituidas
BR0307408A (pt) Tripeptìdeos tendo um éter de hidroxipolina de uma quinolina substituìda para a inibição de ns3 (hepatite c)
AR002723A1 (es) Compuestos derivados de quinazolina y procedimiento para prepararlos, compuesto intermediarios utiles en dicho procedimiento, su uso
MA28598B1 (fr) Combinaisons de glycopyrrolate et d'agonistes de recepteur beta2-adrenergique
RU2004135304A (ru) Производные 2,6-хинолинила и 2,6-нафтила, способы их получения и их применение в качестве ингибиторов vla-4
RU2000126841A (ru) Производные амида и антагонисты ноцицептина
KR970703333A (ko) 5-HT_1A 길항제로서의 피페라진 유도체(Piperazine derivatives as 5-HT_1A antagonists)
CA2982267C (en) Novel dgat2 inhibitors
AU575558B2 (en) Pharmaceutical 2-(carboxy or subst. amino methyl) imidazole
NZ612544A (en) Heterocyclic compounds suitable for the treatment of dyslipidemia
PT100942A (pt) Agentes antifungicos de triazole, processo para a sua preparacao e composicoes farmaceuticas que os contem
CZ246695A3 (en) Amidine derivatives, their use, process for preparing such derivatives and pharmaceutical composition containing thereof

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed